Undecimal Bio is a platform biotechnology company spun out of Eleven Therapeutics that develops targeted delivery of siRNA therapeutics beyond the liver. Its proprietary DELiveri platform pairs massive-scale combinatorial chemistry with agentic AI to identify ligand conjugates that carry RNA medicines into defined cell types, using cells as single-molecule-resolution delivery sensors. The company operates laboratories at the Cancer Research UK Cambridge Institute alongside a team in Tel Aviv, and initially applies the platform to renovascular diseases.
1
Round
1
Industry
3
Tags
Oct 13, 2026
Latest raise
Funding activity · 1 round
Oct 13, 2026
$18M
Seed
Led by IQ Capital
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
